Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy

Therapy related‐acute myeloid leukemia (t‐AML) and myelodysplastic syndrome (t‐MDS) are complications of chemotherapy and/or radiation therapy for malignant diseases. In this report, we describe a patient with advanced lung adenocarcinoma who developed autoimmune hemolytic anemia and MDS associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakatsuru, Kousei, Tsubouchi, Kazuya, Hirahata, Minori, Nakashima, Tadayuki, Takahata, Yuriko, Okamatsu, Yuki, Shiraishi, Yoshimasa, Okamoto, Isamu, Harada, Taishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396777/
https://www.ncbi.nlm.nih.gov/pubmed/37337950
http://dx.doi.org/10.1111/1759-7714.15005
Descripción
Sumario:Therapy related‐acute myeloid leukemia (t‐AML) and myelodysplastic syndrome (t‐MDS) are complications of chemotherapy and/or radiation therapy for malignant diseases. In this report, we describe a patient with advanced lung adenocarcinoma who developed autoimmune hemolytic anemia and MDS associated with a combination of atezolizumab and platinum‐based chemotherapy. The patient showed progression from t‐MDS to t‐AML 20 months after the treatment was initiated. A combination of immune checkpoint inhibitor (ICI) and chemotherapy may increase the risk of developing therapy‐related myeloid neoplasms. As the prognosis of t‐AML and t‐MDS is poorer than that of de novo AML and MDS, proper surveillance, follow‐up, and treatment are needed throughout the course of immunotherapy.

Ejemplares similares